| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
|
Medicine details |
|
| Medicine name | darolutamide (Nubeqa®) |
| Formulation | 300 mg tablet |
| Reference number | 3306 |
| Indication | Treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/02/2020 |
| NICE guidance | |
| Commercial arrangement | PAS |